Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Conditions
Interventions
ASP0113
Placebo
Locations
83
United States
Site US10028
Birmingham, Alabama, United States
Site US10044
Tucson, Arizona, United States
Site US10035
San Francisco, California, United States
Site US10026
Stanford, California, United States
Site US10030
Tampa, Florida, United States
Site US10012
Atlanta, Georgia, United States
Start Date
September 11, 2013
Primary Completion Date
September 28, 2017
Completion Date
March 1, 2022
Last Updated
October 24, 2024
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions